KPTI241220C5000
- 0.00
- 0.000.00%
Karyopharm Therapeutics Newsroom
Karyopharm Announces the Appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications
Karyopharm Therapeutics Will Update On Endometrial Cancer Program Following US FDA Meet
Karyopharm Therapeutics Provides Endometrial Cancer Program Update
Express News | Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm to Participate at the Piper Sandler 36th Annual Healthcare Conference
Express News | Karyopharm Therapeutics Announces the Appointment of Chief Accounting Officer
Press Release: Karyopharm Therapeutics Announces the Appointment of Chief Accounting Officer
Karyopharm to Present Selinexor Data at the 66th American Society of Hematology Annual Meeting and Exposition
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Cautious Hold Rating on Karyopharm Therapeutics Amid Incremental Revenue Growth and Pending Clinical Trial Outcomes
Piper Sandler Maintains Karyopharm Therapeutics(KPTI.US) With Buy Rating, Raises Target Price to $5
Express News | Piper Sandler Maintains Overweight on Karyopharm Therapeutics, Raises Price Target to $5
RBC Capital Maintains Karyopharm Therapeutics(KPTI.US) With Buy Rating, Maintains Target Price $3
Barclays Maintains Karyopharm Therapeutics(KPTI.US) With Buy Rating, Maintains Target Price $5
Karyopharm Therapeutics Inc. (KPTI) Q3 2024 Earnings Call Transcript Summary
H.C. Wainwright Maintains Karyopharm Therapeutics(KPTI.US) With Buy Rating, Maintains Target Price $7
Karyopharm Therapeutics: Strong Demand and Strategic Initiatives Justify Buy Rating
Karyopharm Therapeutics | 10-Q: Q3 2024 Earnings Report
Karyopharm Therapeutics (KPTI) Reports Q3 Loss, Tops Revenue Estimates